Oakbrook Investments LLC lessened its stake in shares of Agilent Technologies Inc (NYSE:A) by 19.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 21,065 shares of the medical research company’s stock after selling 5,070 shares during the quarter. Oakbrook Investments LLC’s holdings in Agilent Technologies were worth $1,411,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. Coastline Trust Co boosted its stake in shares of Agilent Technologies by 140.2% in the fourth quarter. Coastline Trust Co now owns 24,695 shares of the medical research company’s stock valued at $1,654,000 after purchasing an additional 14,415 shares during the period. Creative Planning boosted its stake in shares of Agilent Technologies by 11.0% in the fourth quarter. Creative Planning now owns 17,113 shares of the medical research company’s stock valued at $1,146,000 after purchasing an additional 1,698 shares during the period. Bank of Montreal Can boosted its stake in shares of Agilent Technologies by 187.3% in the fourth quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock valued at $49,693,000 after purchasing an additional 483,721 shares during the period. New England Research & Management Inc. boosted its stake in shares of Agilent Technologies by 79.2% in the fourth quarter. New England Research & Management Inc. now owns 11,650 shares of the medical research company’s stock valued at $780,000 after purchasing an additional 5,150 shares during the period. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Agilent Technologies by 9.4% in the third quarter. Parametric Portfolio Associates LLC now owns 616,303 shares of the medical research company’s stock valued at $39,567,000 after purchasing an additional 52,920 shares during the period.
Shares of Agilent Technologies Inc (NYSE:A) opened at $73.07 on Friday. The firm has a market cap of $23,318.67, a P/E ratio of 34.80, a P/E/G ratio of 2.18 and a beta of 1.28. Agilent Technologies Inc has a 1-year low of $47.05 and a 1-year high of $73.21. The company has a quick ratio of 2.85, a current ratio of 3.30 and a debt-to-equity ratio of 0.37.
Agilent Technologies (NYSE:A) last issued its earnings results on Monday, November 20th. The medical research company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.62 by $0.05. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.17 billion. Agilent Technologies had a net margin of 15.30% and a return on equity of 16.95%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.59 earnings per share. equities analysts forecast that Agilent Technologies Inc will post 2.58 EPS for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be issued a $0.149 dividend. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. The ex-dividend date of this dividend is Friday, December 29th. This represents a $0.60 annualized dividend and a yield of 0.82%. Agilent Technologies’s dividend payout ratio (DPR) is 28.57%.
In other Agilent Technologies news, VP Mark Doak sold 4,154 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The shares were sold at an average price of $67.00, for a total transaction of $278,318.00. Following the sale, the vice president now owns 68,270 shares of the company’s stock, valued at $4,574,090. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Michael R. Mcmullen sold 43,703 shares of the firm’s stock in a transaction that occurred on Friday, January 5th. The stock was sold at an average price of $70.00, for a total transaction of $3,059,210.00. Following the sale, the chief executive officer now directly owns 302,837 shares in the company, valued at approximately $21,198,590. The disclosure for this sale can be found here. In the last three months, insiders have sold 198,141 shares of company stock worth $13,830,045.
Several research firms have recently commented on A. Robert W. Baird reissued a “buy” rating and issued a $76.00 price objective on shares of Agilent Technologies in a research note on Thursday. Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 price objective on shares of Agilent Technologies in a research note on Tuesday, September 26th. Cowen reissued a “hold” rating and issued a $65.00 price objective on shares of Agilent Technologies in a research note on Thursday, September 28th. Evercore ISI initiated coverage on shares of Agilent Technologies in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $75.00 price objective for the company. Finally, Barclays reaffirmed a “buy” rating and issued a $74.00 target price on shares of Agilent Technologies in a report on Monday, January 8th. Six investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Agilent Technologies presently has a consensus rating of “Buy” and a consensus target price of $69.25.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/20/agilent-technologies-inc-a-shares-sold-by-oakbrook-investments-llc.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.